The “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market<RootsAnalysis>

Key Inclusions
 A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
 An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
 An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
 An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.

Contact Us:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Leave a Reply

Your email address will not be published. Required fields are marked *